Pages Menu
Categories Menu

Posted by on Oct 19, 2016 in Foundation NewsLine, Type A, Type B |

Sanofi Genzyme Phase 2/3 Clinical Trial

sanofi genzyme logo

Dear NNPDF ASMD Patient and Family Community,

The National Niemann-Pick Disease Foundation (NNPDF) is pleased to advise our Niemann-Pick Disease Type A/B & Type B (aka: Acid Sphingomyelinase Deficiency ~ ASMD) Disease patient’s & family community that Sanofi Genzyme has received FDA authorization to begin recruiting for the phase 2/3 clinical trial of Olipudase Alfa for adult patients in the United States (U.S.).   The first U.S. clinical trial site will be at Emory University in Atlanta, Georgia under the direction of Dr. William Wilcox.

Follow the links below to read the full letter along with a press release from July 6, 2016.

We WILL Persevere in our Quest for a Cure!

Letter to ASMD Community         Press Release

10/19/2016 jjb